SCHEMBL3371667

SCHEMBL3371667

CCOC(Cc1ccc(OCc2csc(-c3ccc(C)cc3)n2)c(F)c1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
PPARA Q07869 11/20 0.42
PPARG P37231 10/20 0.42
PPARD Q03181 4/20 0.41
FFAR1 O14842 1/20 0.41
ALOX5 P09917 1/20 0.41
PSEN1 P49768 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
TP53 P04637 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369630 0.93 LMNA (0.43) LMNAPPARAPPARGPPARDFFAR1
SCHEMBL3372318 0.93 PPARG (0.47) LMNAPPARAPPARGPPARDNPC1
SCHEMBL3370374 0.91 PPARA (0.43) PPARAPPARGPPARDFFAR1ALOX5
SCHEMBL3369163 0.91 LMNA (0.45) LMNAPPARAPPARGPPARDMAPT
SCHEMBL3371385 0.91 PPARA (0.44) PPARAPPARGPPARDALOX5PSEN1
SCHEMBL3374208 0.91 PPARA (0.46) PPARAPPARGPPARDALOX5PSEN1
SCHEMBL3368960 0.91 ALOX5 (0.51) LMNAPPARAPPARGPPARDFFAR1
SCHEMBL3374527 0.88 RAB9A (0.44) LMNAPPARAPPARGPPARDFFAR1
SCHEMBL3373634 0.85 FFAR1 (0.39) LMNAPPARAPPARGPPARDFFAR1
SCHEMBL3402718 0.84 ALOX5 (0.49) LMNAPPARAPPARGPPARDFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR LMNA 3464/4885PPARA 287/4885PPARG 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.